IS4970A - Setnar 6,6-heteró-bísýklískar afleiður - Google Patents

Setnar 6,6-heteró-bísýklískar afleiður

Info

Publication number: IS4970A
Authority: IS; Iceland
Prior art keywords: hetero; determines; bicyclic derivatives; bicyclic; derivatives
Prior art date: 1996-08-27

Application number

IS4970A

Other languages

English (en)

Inventor

Liang Chen Yuhpyng

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-27

Filing date

1999-02-05

Publication date

1999-02-05

1999-02-05 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

1999-02-05 Publication of IS4970A publication Critical patent/IS4970A/is

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Nutrition Science (AREA)
Virology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pregnancy & Childbirth (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Addiction (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)

IS4970A 1996-08-27 1999-02-05 Setnar 6,6-heteró-bísýklískar afleiður IS4970A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2465996P	1996-08-27	1996-08-27
PCT/IB1997/000904 WO1998008846A1 (en)	1996-08-27	1997-07-21	Substituted 6,6-hetero-bicyclic derivatives

Publications (1)

Publication Number	Publication Date
IS4970A true IS4970A (is)	1999-02-05

Family

ID=21821740

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4970A IS4970A (is)	1996-08-27	1999-02-05	Setnar 6,6-heteró-bísýklískar afleiður

Country Status (40)

Country	Link
EP (1)	EP0925298B1 (is)
JP (1)	JP2000502722A (is)
KR (1)	KR100457759B1 (is)
CN (2)	CN1191236C (is)
AP (1)	AP1164A (is)
AR (2)	AR009321A1 (is)
AT (1)	ATE264327T1 (is)
AU (1)	AU726771C (is)
BG (1)	BG64316B1 (is)
BR (1)	BR9711262A (is)
CA (1)	CA2263913C (is)
CO (1)	CO4930259A1 (is)
CZ (1)	CZ67799A3 (is)
DE (1)	DE69728676T2 (is)
DK (1)	DK0925298T3 (is)
DZ (1)	DZ2299A1 (is)
EA (1)	EA002607B1 (is)
ES (1)	ES2216157T3 (is)
GT (1)	GT199700093A (is)
HR (1)	HRP970452A2 (is)
ID (1)	ID18189A (is)
IL (1)	IL128049A (is)
IS (1)	IS4970A (is)
MY (1)	MY132671A (is)
NO (1)	NO316273B1 (is)
NZ (1)	NZ333728A (is)
OA (1)	OA10980A (is)
PA (1)	PA8435001A1 (is)
PE (1)	PE108698A1 (is)
PL (1)	PL331988A1 (is)
PT (1)	PT925298E (is)
SI (1)	SI0925298T1 (is)
SK (1)	SK22599A3 (is)
TN (1)	TNSN97144A1 (is)
TR (1)	TR199900408T2 (is)
TW (1)	TW477787B (is)
UA (1)	UA66345C2 (is)
WO (1)	WO1998008846A1 (is)
YU (1)	YU35697A (is)
ZA (1)	ZA977652B (is)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6124289A (en) *	1996-07-24	2000-09-26	Dupont Pharmaceuticals Co.	Azolo triazines and pyrimidines
US7094782B1 (en)	1996-07-24	2006-08-22	Bristol-Myers Squibb Company	Azolo triazines and pyrimidines
US6060478A (en) *	1996-07-24	2000-05-09	Dupont Pharmaceuticals	Azolo triazines and pyrimidines
US6191131B1 (en)	1997-07-23	2001-02-20	Dupont Pharmaceuticals Company	Azolo triazines and pyrimidines
US6313124B1 (en)	1997-07-23	2001-11-06	Dupont Pharmaceuticals Company	Tetrazine bicyclic compounds
EA003188B1 (ru)	1996-08-06	2003-02-27	Пфайзер Инк	Замещенные пиридо- или пиримидосодержащие 6,6- или 6,7-бициклические производные
CA2281525A1 (en)	1997-02-18	1998-08-20	Neurocrine Biosciences, Inc.	Biazacyclic crf antagonists
ATE250035T1 (de) *	1997-04-22	2003-10-15	Janssen Pharmaceutica Nv	Chinolin- und chinazolin-derivate als crf antagonisten
NL1010018C2 (nl) *	1997-09-09	1999-03-10	Duphar Int Res	Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
PT1129091E (pt)	1998-11-12	2003-02-28	Neurocrine Biosciences Inc	Antagonistas de receptor de crf e metodos relacionados
PT1129096E (pt)	1998-11-12	2003-09-30	Neurocrine Biosciences Inc	Antagonistas de receptor de crf e metodos de tratamento relacionados com os mesmos
ES2226785T3 (es)	1999-02-12	2005-04-01	Smithkline Beecham Plc	Derivados de fenilurea como antagonistas de los receptores de orexina.
US6432989B1 (en) *	1999-08-27	2002-08-13	Pfizer Inc	Use of CRF antagonists to treat circadian rhythm disorders
ES2258476T3 (es)	1999-09-30	2006-09-01	Neurogen Corporation	Ciertos heterociclos sustituidos con alquilendiaminas.
ES2258479T3 (es)	1999-10-01	2006-09-01	JOHNSON & JOHNSON CONSUMER COMPANIES, INC.	Tecnica que permite calmar a las personas con la ayuda de composiciones de tratamientos personales.
IL139197A0 (en)	1999-10-29	2001-11-25	Pfizer Prod Inc	Use of corticotropin releasing factor antagonists and related compositions
US6525067B1 (en) *	1999-11-23	2003-02-25	Pfizer Inc	Substituted heterocyclic derivatives
ATE319103T1 (de)	2000-01-26	2006-03-15	Em Microelectronic Marin Sa	Verfahren zur prüfung einer integrierten schaltung mit vertraulichen software- oder hardware-elementen
CA2398956A1 (en) *	2000-02-14	2001-08-16	Japan Tobacco Inc.	A pharmaceutical composition for prophylaxis or therapy of a postoperative stress
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2001261850A1 (en) *	2000-05-18	2001-11-26	Neurocrine Biosciences, Inc.	Crf receptor antagonists and methods relating thereto
JP4524072B2 (ja)	2000-10-23	2010-08-11	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	新規化合物
CA2446514A1 (en)	2001-04-30	2002-11-07	Glaxo Group Limited	Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
GB0117396D0 (en) *	2001-07-17	2001-09-05	Glaxo Group Ltd	Chemical compounds
GB2384563A (en)	2002-01-29	2003-07-30	Johnson & Johnson Consumer	Method of measuring the stress or relaxation level of a mammal
MXPA04010267A (es)	2002-04-19	2005-02-03	Smithkline Beecham Corp	Compuestos novedosos.
US7067658B2 (en) *	2002-09-30	2006-06-27	Bristol-Myers Squibb Company	Pyridino and pyrimidino pyrazinones
KR101078098B1 (ko)	2003-01-14	2011-10-28	아레나 파마슈티칼스, 인크.	대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된장애의 예방 및 치료
GB0308208D0 (en)	2003-04-09	2003-05-14	Glaxo Group Ltd	Chemical compounds
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AR045697A1 (es) *	2003-07-14	2005-11-09	Arena Pharm Inc	Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo
JP2007501822A (ja)	2003-08-12	2007-02-01	エフ．ホフマン−ラ　ロシュ　アーゲー	コルチコトロピン放出性因子（ｃｒｆ）アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン
CA2534785A1 (en)	2003-08-12	2005-02-17	Robin Douglas Clark	Tetrahydroquinazoline derivatives as cfr antagonists
JP2006232849A (ja) *	2003-08-13	2006-09-07	Japan Tobacco Inc	含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AU2005215257A1 (en) *	2004-02-13	2005-09-01	Pfizer Products Inc.	Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
DE102004018198A1 (de) *	2004-04-15	2005-11-03	Merck Patent Gmbh	Sulfonamide
EP1828186A1 (en)	2004-12-13	2007-09-05	Sunesis Pharmaceuticals, Inc.	Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
MY145343A (en)	2005-03-25	2012-01-31	Glaxo Group Ltd	Novel compounds
PE20061193A1 (es)	2005-03-25	2006-12-02	Glaxo Group Ltd	DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US20080096905A1 (en)	2005-03-25	2008-04-24	Glaxo Group Limited	Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US20090137550A1 (en)	2005-03-25	2009-05-28	Glaxo Group Limited	Novel Compounds
JP4318744B2 (ja)	2005-03-31	2009-08-26	ファイザー・プロダクツ・インク	シクロペンタピリジンおよびテトラヒドロキノリン誘導体
RU2467007C2 (ru)	2005-12-21	2012-11-20	Эбботт Лэборетриз	Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
ES2395386T3 (es)	2005-12-21	2013-02-12	Abbott Laboratories	Compuestos antivirales
RU2441869C2 (ru)	2005-12-21	2012-02-10	Эбботт Лэборетриз	Противовирусные соединения
NZ576278A (en)	2006-10-19	2011-12-22	Signal Pharm Llc	Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
CA2672737A1 (en)	2006-12-20	2008-11-06	Abbott Laboratories	Anti-viral compounds
BRPI0811745B1 (pt) *	2007-05-17	2019-06-04	Helperby Therapeutics Limited	Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica --
WO2011156889A1 (en) *	2010-06-14	2011-12-22	Trt Pharma Inc.	Novel modulators of nrf2 and uses thereof
SG188548A1 (en)	2010-09-22	2013-04-30	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
MX2015001099A (es) *	2012-08-24	2015-04-08	Hoffmann La Roche	Nuevos derivados biciclicos de piridina.
RU2718918C2 (ru)	2014-01-21	2020-04-15	Ньюрокрайн Байосайенсиз, Инк.	Антагонисты рецептора cfr1 для лечения врожденной гиперплазии коры надпочечников
PL3242666T3 (pl)	2015-01-06	2025-02-17	Arena Pharmaceuticals, Inc.	Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
HUE047477T2 (hu)	2015-06-04	2020-04-28	Pfizer	Palbociclib szilárd dózisformái
HUE060476T2 (hu)	2015-06-22	2023-03-28	Arena Pharm Inc	(R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
JP6563623B1 (ja)	2016-08-15	2019-08-21	ファイザー・インク	ピリドピリミジノンｃｄｋ２／４／６阻害剤
CN110177796B (zh) *	2017-01-06	2022-04-08	阿斯克里斯有限公司	喹啉酮衍生物及其用于预防或治疗变应性疾病的药物组合物
US12156866B2 (en)	2018-06-06	2024-12-03	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
BR112021010847A2 (pt)	2018-12-07	2021-09-08	Neurocrine Biosciences Inc.	Antagonista de receptor de crf1, formulações farmacêuticas e formas sólidas das mesmas para o tratamento de hiperplasia adrenal congênita
US12383536B2 (en)	2019-09-27	2025-08-12	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods of use
CN115160221B (zh) *	2022-07-26	2024-10-18	恩祺生物科技(上海)有限公司	德立替尼晶型化合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6765008B1 (en) *	1992-12-17	2004-07-20	Pfizer Inc	Pyrrolopyrimidines as CRF antagonists
TW444018B (en) *	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
TW574214B (en) *	1994-06-08	2004-02-01	Pfizer	Corticotropin releasing factor antagonists
NZ284846A (en) *	1994-06-16	1998-12-23	Pfizer	1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
EP0729758A3 (en) *	1995-03-02	1997-10-29	Pfizer	Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
CA2194756A1 (en) *	1995-05-12	1996-11-14	Jun Yuan	Novel deazapurine derivatives; a new class of crf1 specific ligands
US6403599B1 (en) *	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
ES2200039T3 (es) *	1995-12-08	2004-03-01	Pfizer Inc.	Derivados heterociclicos sustituidos como antagonistas de crf.

1997
- 1997-07-15 TW TW086109990A patent/TW477787B/zh not_active IP Right Cessation
- 1997-07-21 DK DK97929464T patent/DK0925298T3/da active
- 1997-07-21 UA UA99020647A patent/UA66345C2/uk unknown
- 1997-07-21 SI SI9730642T patent/SI0925298T1/xx unknown
- 1997-07-21 AT AT97929464T patent/ATE264327T1/de not_active IP Right Cessation
- 1997-07-21 PT PT97929464T patent/PT925298E/pt unknown
- 1997-07-21 PL PL97331988A patent/PL331988A1/xx unknown
- 1997-07-21 JP JP10511427A patent/JP2000502722A/ja active Pending
- 1997-07-21 CZ CZ99677A patent/CZ67799A3/cs unknown
- 1997-07-21 CN CNB021020574A patent/CN1191236C/zh not_active Expired - Fee Related
- 1997-07-21 EA EA199900166A patent/EA002607B1/ru not_active IP Right Cessation
- 1997-07-21 IL IL12804997A patent/IL128049A/en not_active IP Right Cessation
- 1997-07-21 CA CA002263913A patent/CA2263913C/en not_active Expired - Fee Related
- 1997-07-21 TR TR1999/00408T patent/TR199900408T2/xx unknown
- 1997-07-21 BR BR9711262A patent/BR9711262A/pt not_active Application Discontinuation
- 1997-07-21 ES ES97929464T patent/ES2216157T3/es not_active Expired - Lifetime
- 1997-07-21 WO PCT/IB1997/000904 patent/WO1998008846A1/en not_active Ceased
- 1997-07-21 CN CNB971973555A patent/CN1138774C/zh not_active Expired - Fee Related
- 1997-07-21 NZ NZ333728A patent/NZ333728A/xx unknown
- 1997-07-21 AU AU33557/97A patent/AU726771C/en not_active Ceased
- 1997-07-21 EP EP97929464A patent/EP0925298B1/en not_active Expired - Lifetime
- 1997-07-21 DE DE69728676T patent/DE69728676T2/de not_active Expired - Fee Related
- 1997-07-21 SK SK225-99A patent/SK22599A3/sk unknown
- 1997-07-21 KR KR10-1999-7001619A patent/KR100457759B1/ko not_active Expired - Fee Related
- 1997-07-30 PA PA19978435001A patent/PA8435001A1/es unknown
- 1997-08-13 GT GT199700093A patent/GT199700093A/es unknown
- 1997-08-21 AP APAP/P/1997/001076A patent/AP1164A/en active
- 1997-08-22 PE PE1997000751A patent/PE108698A1/es not_active Application Discontinuation
- 1997-08-22 HR HR60/024,659A patent/HRP970452A2/hr not_active Application Discontinuation
- 1997-08-25 AR ARP970103851A patent/AR009321A1/es not_active Application Discontinuation
- 1997-08-25 ID IDP972952A patent/ID18189A/id unknown
- 1997-08-26 TN TNTNSN97144A patent/TNSN97144A1/fr unknown
- 1997-08-26 CO CO97049282A patent/CO4930259A1/es unknown
- 1997-08-26 MY MYPI97003918A patent/MY132671A/en unknown
- 1997-08-26 ZA ZA977652A patent/ZA977652B/xx unknown
- 1997-08-26 YU YU35697A patent/YU35697A/sr unknown
- 1997-08-26 DZ DZ970149A patent/DZ2299A1/fr active
1999
- 1999-02-05 IS IS4970A patent/IS4970A/is unknown
- 1999-02-22 BG BG103192A patent/BG64316B1/bg unknown
- 1999-02-25 NO NO19990892A patent/NO316273B1/no not_active IP Right Cessation
- 1999-02-25 OA OA9900039A patent/OA10980A/en unknown
2001
- 2001-01-10 AR ARP010100097A patent/AR026826A1/es unknown

Also Published As

Publication number	Publication date
IL128049A0 (en)	1999-11-30
SI0925298T1 (en)	2004-08-31
DE69728676T2 (de)	2004-09-30
HRP970452A2 (en)	1998-08-31
AP1164A (en)	2003-06-30
EA199900166A1 (ru)	1999-08-26
CN1228091A (zh)	1999-09-08
KR20000035898A (ko)	2000-06-26
AR026826A1 (es)	2003-02-26
PA8435001A1 (es)	2002-07-30
MY132671A (en)	2007-10-31
AU3355797A (en)	1998-03-19
OA10980A (en)	2001-11-02
BR9711262A (pt)	1999-08-17
PT925298E (pt)	2004-07-30
UA66345C2 (en)	2004-05-17
EP0925298B1 (en)	2004-04-14
EA002607B1 (ru)	2002-06-27
CN1138774C (zh)	2004-02-18
PL331988A1 (en)	1999-08-16
HK1019597A1 (en)	2000-02-18
WO1998008846A1 (en)	1998-03-05
AU726771B2 (en)	2000-11-23
ZA977652B (en)	1999-02-26
KR100457759B1 (ko)	2004-11-18
DZ2299A1 (fr)	2002-12-25
DK0925298T3 (da)	2004-08-09
NO316273B1 (no)	2004-01-05
DE69728676D1 (de)	2004-05-19
ATE264327T1 (de)	2004-04-15
CN1367169A (zh)	2002-09-04
EP0925298A1 (en)	1999-06-30
TNSN97144A1 (fr)	2005-03-15
CA2263913A1 (en)	1998-03-05
BG103192A (en)	1999-09-30
CA2263913C (en)	2004-06-29
BG64316B1 (bg)	2004-09-30
NO990892L (no)	1999-02-25
CN1191236C (zh)	2005-03-02
ID18189A (id)	1998-03-12
GT199700093A (es)	1999-02-04
TW477787B (en)	2002-03-01
NO990892D0 (no)	1999-02-25
JP2000502722A (ja)	2000-03-07
AP9701076A0 (en)	1997-10-31
IL128049A (en)	2004-12-15
NZ333728A (en)	2000-11-24
ES2216157T3 (es)	2004-10-16
YU35697A (en)	1999-11-22
PE108698A1 (es)	1999-01-23
SK22599A3 (en)	2000-07-11
TR199900408T2 (xx)	1999-05-21
CZ67799A3 (cs)	1999-11-17
AR009321A1 (es)	2000-04-12
AU726771C (en)	2004-11-11
CO4930259A1 (es)	2000-06-27

Publication	Publication Date	Title
IS4970A (is)	1999-02-05	Setnar 6,6-heteró-bísýklískar afleiður
ATE340176T1 (de)	2006-10-15	Substituierte 6,5-heterobicyclische-derivate
ATE435861T1 (de)	2009-07-15	12,13-cyclopropan-epothilonderivate
DK1000048T3 (da)	2003-03-03	Substituerede 1,2,3,4-tetrahydronapthalenderivater
PT901474E (pt)	2006-07-31	Derivados de aril-pirimidina.
NO2006016I1 (no)	2006-11-27	7,8,9,10-tetrahydro-6H-6,10-metanoazepinoÄ4,5-gÜkinoksalintartrat
PT993456E (pt)	2005-01-31	4,5-diaril-imidazoles 2-substituidos
DE69718771D1 (de)	2003-03-06	Substituierte 1,2,3,4-tetrahydronaphthalinderivate
FI952424L (fi)	1995-11-20	11,21-bisfenyyli-19-norpregaanijohdannaisia
BR9506532A (pt)	1997-09-16	1,2,3,4,-Tetraidro-5-Nitro-Pirimidinas substituidas
TR199800988A3 (tr)	1998-12-21	5' Deoksi-Sitidin türevleri.
ATE246199T1 (de)	2003-08-15	3-descladinose-2,3-anhydroerythromycin-derivate
ATE227282T1 (de)	2002-11-15	2,4-diaminopyrimidin-derivate
NO20003825D0 (no)	2000-07-26	1,3,4 - oxadiazolonderivater
DE69714358D1 (de)	2002-09-05	9,10-disubstituierte campothecinderivate mit antitumoraktivität
ATE199901T1 (de)	2001-04-15	10,11-dihydro-10-oxo-5h-dibenz(b,f)azepin-5- carboxamidderivate
TR28915A (tr)	1997-08-06	Naftokinon türevleri.
ATE240941T1 (de)	2003-06-15	1,25-dihydroxy-16,22,23-trisdehydro- cholecalciferol-derivate
DK1068200T3 (da)	2005-06-20	2,4,4-trisubstituerede-1,3-dioxolanfungicider
ID24047A (id)	2000-07-06	Turunan 5-tersubstitusi-3-oksaziazolil 1,6-naftiridin-2 1h-on
NO993024D0 (no)	1999-06-18	Polysakkarid-peptid-derivater
BR9708948A (pt)	1999-08-03	1,3 - Benzodioxois substituídos
BR9508248A (pt)	1997-11-04	1,2,4,6-Tiatriazinas herbicidas
BR9510036A (pt)	1997-10-28	Derivados de 1,3,4-oxadiazina
TR199700927A3 (tr)	1999-03-22	N-Benzilazolyum türevleri.